NAD+ Longevity Formula
Score Breakdown
Executive Summary
The NAD+ Longevity Formula demonstrates solid clinical backing with 22 validated studies across its key ingredients. The formulation features a robust 500mg dose of NAD+ that meets therapeutic thresholds established in clinical research, paired with resveratrol at clinically meaningful levels. Key Strengths: • NAD+ dose exceeds minimum effective dose (500mg vs 250mg threshold) • Strong safety profile with no severe interactions identified • All 22 citations verified with 94%+ fuzzy match accuracy Areas for Improvement: • Quercetin dose is below optimal range (250mg vs 500-1000mg recommended) • Consider adding bioavailability enhancers (piperine, phospholipids)
Ingredient Analysis
Supporting Studies (2)
Safety Warnings
Resveratrol and quercetin may enhance anticoagulant effects.
Claims Audit
| Claim | Status | FTC Risk |
|---|---|---|
| “Supports cellular energy” | SUBSTANTIATED | LOW |
| “Promotes healthy aging” | PARTIALLY SUBSTANTIATED | MODERATE |
| “Reverses aging” | NOT SUBSTANTIATED | HIGH |
Verification Status
Validity Period
Embed Badge
<script src="https://theclinicalindex.com/badge/TCI-2026-E5C76E38.js"></script>
Actions
Generated by The Clinical Index · January 6, 2026